Metagenomi, Inc. Common Stock (MGX) Stock Score, Valuation & Financial Research
Metagenomi, Inc. Common Stock is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 21/100.
Quick answer for MGX
Metagenomi, Inc. Common Stock currently has a Wall Street Score of 21/100. The stored market price is $1.16. Its financial score is 12/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Metagenomi, Inc. Common Stock does
Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases. Metagenomi has established several key collaborations: a strategic alliance with ModernaTX, Inc. to explore new genome editing systems for in vivo human therapeutic applications; a development and licensing agreement with Affini-T Therapeutics, Inc. to create and commercialize gene-edited T-cell receptor therapies for human cancer; and a partnership with Ionis Pharmaceuticals, Inc. to research, develop, and market investigational
MGX financial snapshot
- Wall Street Score:
- 21/100
- Current price:
- $1.16
- Market capitalization:
- $43.7M
- Revenue:
- $22.3M
- Net income:
- $-85.9M
- Free cash flow:
- $-89.5M
- Cash:
- $25.3M
- Total debt:
- $39.2M
- EPS:
- -2.36
- Financial score:
- 12/100
- Valuation score:
- 0/100
- Revenue score:
- 5/100
What stands out
- Reported year-over-year revenue growth is -0.1%.
- Free cash flow is $-89.5M, showing cash burn in the current stored period.
- The balance sheet shows $25.3M of cash versus $39.2M of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 12/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research MGX
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.